The short answer
Oxyntomodulin is a naturally occurring 37-residue gut peptide produced from proglucagon that activates both the GLP-1 and glucagon receptors. It is the endogenous proof that combined GLP-1 and glucagon agonism is physiologically coherent, and the precedent behind survodutide and mazdutide.
Key facts
- Type
- Endogenous gut peptide
- Length
- 37 residues
- Molecular weight
- ~4,422 Da
- Molecular formula
- C192H295N59O60S
- PubChem CID
- 16144019
- Precursor
- Proglucagon
- Receptors
- GLP-1R and glucagon receptor
- Drugs built on it
- Survodutide, mazdutide
Where it comes from
Oxyntomodulin is produced by post-translational processing of proglucagon in intestinal L cells, the same precursor protein that yields GLP-1. Which peptides emerge depends on which processing enzymes are present, which is why the pancreas and the intestine generate different products from identical genetic material. Oxyntomodulin is released after meals alongside GLP-1.
Why it activates two receptors
Its sequence contains the full glucagon sequence with an eight-residue C-terminal extension. That shared ancestry means it retains meaningful affinity for the glucagon receptor while also engaging GLP-1R, though with lower potency at each than the dedicated ligands. It is not a strong agonist at either. It is a moderate agonist at both.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Why that combination is interesting rather than contradictory
Glucagon raises blood glucose, so pairing it with GLP-1 looks self-defeating. Physiologically it is not: glucagon also increases energy expenditure and drives hepatic lipid oxidation, and sufficient concurrent GLP-1 signalling offsets the glycaemic effect. Oxyntomodulin demonstrates that the body itself deploys this combination, which is the strongest possible argument that the pharmacology is coherent.
What was built on it
Survodutide and mazdutide are engineered GLP-1/glucagon dual agonists, with mazdutide derived from oxyntomodulin directly. Retatrutide extends the same logic by adding GIP on top, making a triple agonist. Every glucagon-containing incretin drug traces its rationale to this peptide.
Why oxyntomodulin itself is not a drug
It has a very short half-life, being subject to DPP-4 and rapid clearance like other native gut peptides, and its potency at each receptor is modest. Engineering was required on both counts: protease resistance and albumin binding for duration, and sequence optimisation to tune the balance of activity between the two receptors deliberately rather than accepting what physiology provides.
Frequently asked questions
Is oxyntomodulin the same as glucagon?
No, but it contains the glucagon sequence plus an eight-residue C-terminal extension, which is why it retains glucagon receptor activity.
Is oxyntomodulin available as a medicine?
No. Its short half-life and modest potency at each receptor mean engineered analogues were developed instead.
Why do GLP-1 and glucagon agonism combine usefully?
Glucagon increases energy expenditure and hepatic lipid oxidation; sufficient GLP-1 signalling offsets its glucose-raising effect. Oxyntomodulin shows the body already uses this combination.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubChemPubChem · Oxyntomodulin (CID 16144019)pubchem.ncbi.nlm.nih.gov
- PubMedZimmermann T et al., BI 456906: a novel GCGR/GLP-1R dual agonist. Mol Metab 2022 (PMID 36356832)pubmed.ncbi.nlm.nih.gov
- PubMedValdecantos MP et al., Dual GLP-1/glucagon receptor agonist G49. Nat Commun 2024 (PMID 39609390)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- GLP-1 Agonists and Alcohol Use: The Trial EvidenceThree randomised trials have tested semaglutide in alcohol use disorder, reporting reduced craving and heavy drinking days. All were small and short.
- SURMOUNT-OSA: Tirzepatide in Obstructive Sleep ApnoeaTirzepatide reduced apnoea-hypopnoea index by 27.4 events per hour at 52 weeks against 4.8 on placebo. The first incretin approved for a non-metabolic use.
- Why GLP-1 Receptors Turn Up in Reward ResearchGLP-1 receptors are expressed in mesolimbic reward circuitry, not only in appetite regions. That expression is the mechanistic basis for the craving findings.
- Why GLP-1 Drugs Matter Before AnaesthesiaDelayed gastric emptying means a fasted patient on a GLP-1 may still have stomach contents. Ultrasound studies, and why this is a mechanism-linked risk.
- GLP-1 Gastrointestinal Safety SignalsGastroparesis, pancreatitis and bowel obstruction have all been raised as GLP-1 signals. What the comparative cohort data shows, and how the compounds differ.